Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia |
| Type de publication | Journal Article |
| Year of Publication | 2016 |
| Auteurs | Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O, Denis G, Buchdahl A-L, Omouri M, Maigne G, Aouba A, Leon N, Berthier S, Liozon E, Park S, Gardin C, Lortholary O, Rossignol J, Fenaux P, Fain O, Braun T |
| Journal | LEUKEMIA RESEARCH |
| Volume | 43 |
| Pagination | 13-17 |
| Date Published | APR |
| Type of Article | Article |
| ISSN | 0145-2126 |
| Mots-clés | Auto immune disorders, Azacitidine, myelodysplastic syndromes |
| Résumé | This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n = 11), both unfavorable (n = 2), but AID improved while MDS/CMML worsened (n = 8) and vice versa (n = 1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings. (C) 2016 Elsevier Ltd. All rights reserved. |
| DOI | 10.1016/j.leukres.2016.02.005 |